FDA Grants Supplemental Approval to AstraZeneca's Calquence

Date : 11/21/2019 @ 4:43PM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7878.0  171.0 (2.22%) @ 4:35PM
Astrazeneca share price Chart

FDA Grants Supplemental Approval to AstraZeneca's Calquence

AstraZeneca (NYSE:AZN)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more AstraZeneca Charts.

By Michael Dabaie

 

The U.S. Food and Drug Administration granted supplemental approval to AstraZeneca PLC (AZN) for Calquence to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

This new approved indication for Calquence provides a new treatment option for patients with CLL or SLL as an initial or subsequent therapy, the FDA said.

The FDA said the approval was part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada. Project Orbis provides a framework for concurrent submission and review of oncology drug applications among the FDA's international partners.

AstraZeneca ADRs were recently up 1% to $47.47.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

November 21, 2019 11:28 ET (16:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200120 06:46:49